Janssen submits Genmab-developed drug for EMA approval
![Photo: Tuala Hjarnø / Genmab / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13383397.ece/ALTERNATES/schema-16_9/doc7i1a4vt0dk714w5ed2v9.jpg)
The European Medicines Council (EMA) has just received a new marketing authorization application for teclistamab, a treatment for relapsed or refractory multiple myeloma, which is a type of bone marrow cancer.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Novartis increases sales of Genmab-developed sclerosis drug
For subscribers